You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Authors' response
  1. S Ewig1,
  2. N Birkner2
  1. 1Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, Herne und Bochum, Germany
  2. 2BQS Institut für Qualität und Patientensicherheit, Duesseldorf, Germany
  1. Correspondence to Dr N Birkner, BQS Institut für Qualität und Patientensicherheit, Kanzlerstr. 4, D-40472 Düsseldorf, Germany; n.birkner{at}bqs-institut.de

https://doi.org/10.1136/thx.2010.149716

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Charles for his important comments.1

    He raises the important question of whether CRB-65 is a useful tool to advise treatment limitations. If only 29% of those who finally died were at high risk of death at initial presentation (CRB-65 risk class 3), such a tool may be of limited value in this regard. In fact, we agree that …

    View Full Text

    Footnotes

    • Linked articles 133884

    • Competing interests None.

    • Provenance and peer review Not commissioned; not externally peer reviewed.

    Linked Articles